



# KMCH INSTITUTE OF HEALTH SCIENCE AND RESEARCH (A Unit of Kovai Medical Center & Hospital) COIMBATORE, TAMILNADU



## DEPARTMENT OF PHARMACOLOGY

### *INSIDE THIS SERIES*

1. Sodium oxybate
2. Respiratory syncytial virus vaccine adjuvanted
3. Phenylephrine & tropicamide
4. Pegunigalsidase alfa-iwxj
5. Fezolinetant
6. Hyaluronic acid & Lidocaine
7. Perfluorohexyloctane
8. Beremagene geperpavec-svdt

### *NEW DRUG UPDATE*



**SERIES 47**

**JUNE 2023**

*Compiled and edited by  
Department of Pharmacology  
KMCHHSR, COIMBATORE*

### *INSIDE THIS SERIES*

9. Epcoritamab-bysp
10. Nalmefene hydrochloride
11. Adalimumab-aaty
12. Sulbactam & Durlobactam
13. Buprenorphine
14. Flotufolostat F 18
15. Nirmatrelvir & Ritonavir
16. Sotagliflozin

*1. Sodium oxybate*

*Date of Approval: May 1, 2023*

**DRUG CLASS:** CNS depressant

**INDICATIONS:** Narcolepsy

**DOSAGE FORMS:** Granules for Extended-Release Oral Suspension

*2. Respiratory syncytial virus vaccine adjuvanted*

*Date of Approval: May 3, 2023*

**DRUG CLASS:** Recombinant protein subunit vaccine

**INDICATIONS:** Prevention of RSV Infection

**DOSAGE FORMS:** Suspension for Intramuscular Injection

*3. Phenylephrine hydrochloride & Tropicamide*

*Date of Approval: May 5, 2023*

**DRUG CLASS:** Alpha-1 adrenergic receptor agonist and anticholinergic

**INDICATIONS:** To induce mydriasis for diagnostic procedures

**DOSAGE FORMS:** Ophthalmic Spray



**4. Pegunigalsidase alfa-iwxj**

*Date of Approval: May 9, 2023*

**DRUG CLASS:** Hydrolytic lysosomal neutral glycosphingolipid - specific enzyme

**INDICATIONS:** Adults with confirmed Fabry Disease

**DOSAGE FORMS:** Intravenous infusion

**5. Fezolinetant**

*Date of Approval: May 12, 2023*

**DRUG CLASS:** Selective neurokinin 3 (NK3) receptor antagonist

**INDICATIONS:** Menopausal Disorders, Hot Flashes

**DOSAGE FORMS:** Tablets

**6. Hyaluronic acid & Lidocaine**

*Date of Approval: May 15, 2023*

**DRUG CLASS:** Dermal filler and a local anesthetic

**INDICATIONS:** Facial Wrinkles

**DOSAGE FORMS:** Intradermal microdroplet injectable gel



**7. Perfluorohexyloctane**

*Date of Approval: May 18, 2023*

**DRUG CLASS:** Semifluorinated alkane

**INDICATIONS:** Dry Eye Disease

**DOSAGE FORMS:** Ophthalmic Solution

**8. Beremagene geperpavec-svdt**

*Date of Approval: May 19, 2023*

**DRUG CLASS:** Herpes-simplex virus type 1 (HSV-1) vector - based gene therapy

**INDICATIONS:** Wounds in patients dystrophic epidermolysis bullosa.

**DOSAGE FORMS:** Topical Gel

**9. Epcoritamab-bysp**

*Date of Approval: May 19, 2023*

**DRUG CLASS:** Bispecific CD20-directed CD3 T-cell engager

**INDICATIONS:** Relapsed or refractory Diffuse Large B-Cell Lymphoma

**DOSAGE FORMS:** S.C injection.



*10. Nalmefene hydrochloride*

*Date of Approval: May 22, 2023*

**DRUG CLASS:** Opioid antagonist

**INDICATIONS:** Opioid Overdose

**DOSAGE FORMS:** Nasal spray

*11. Adalimumab-aaty (biosimilar)*

*Date of Approval: May 23, 2023*

**DRUG CLASS:** TNF blocker

**INDICATIONS:** Rheumatoid arthritis, Juvenile Idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Crohn's disease, Ulcerative colitis, Plaque psoriasis, and Hidradenitis suppurativa.

**DOSAGE FORMS:** S.C injection

*12. Sulbactam & Durlobactam*

*Date of Approval: May 23, 2023*

**DRUG CLASS:** Beta-lactam antibacterial (Sulbactam) & beta lactamase inhibitor (Durlobactam)

**INDICATIONS:** Acinetobacter Pneumonia

**DOSAGE FORMS:** IV Infusion



**13. Buprenorphine**

*Date of Approval: May 23, 2023*

**DRUG CLASS:** Partial opioid agonist

**INDICATIONS:** Opioid Use Disorder

**DOSAGE FORMS:** Extended-Release Injection

**14. Flotufolastat F 18**

*Date of Approval: May 25, 2023*

**DRUG CLASS:** Targeted radio hybrid diagnostic imaging agent

**INDICATIONS:** Positron Emission Tomography Imaging, Diagnosis and Investigation

**DOSAGE FORMS:** IV bolus injection

**15. Nirmatrelvir & Ritonavir**

*Date of Approval: May 25, 2023*

**DRUG CLASS:** Nirmatrelvir, SARS-CoV-2 main protease inhibitor & Ritonavir, a HIV-1 protease inhibitor and CYP3A inhibitor

**INDICATIONS:** COVID-19

**DOSAGE FORMS:** Tablets





## 16. Sotagliflozin

*Date of Approval: May 26, 2023*

**DRUG CLASS:** SGLT2 inhibitor

**INDICATIONS:** Heart Failure

**DOSAGE FORMS:** Tablets



shutterstock.com · 655158958







We're on the Web! Visit us at:  
<http://www.kmchihsr.edu.in>



Email your suggestions to :  
[hodpharmacology@kmchihsr.edu.in](mailto:hodpharmacology@kmchihsr.edu.in)






DEDICATED TO  
**DISCOVERY**

COMMITTED TO  
**CARE**



HEALTHSLOGANS.COM



To raise new questions, new possibilities, to regard old problems from a new angle, requires creative imagination and marks real advance in science.

— *Albert Einstein* —

AZ QUOTES